Analysis of HER2 testing in breast cancer: disparities, cost-effectiveness, and patterns of care
HER2 breast cancer is an aggressive disease that occurs in 20 - 30% of the breast cancer population. Treatment for HER2 breast cancer includes use of an anti-HER2 monoclonal antibody, trastuzumab. Testing for HER2 is of critical importance due to the adverse side effects and substantial costs associ...
| Main Author: | |
|---|---|
| Published: |
Georgia Institute of Technology
2009
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1853/29711 |